Dr. Robin L. Smith, the Chairman and CEO of NeoStem, Inc. (NBS), Interviews with The Wall Street Transcript

Wall Street Transcript

67 WALL STREET, New York - September 13, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Reimbursement Trends

Companies include: Neostem, Inc. (NBS) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the Chairman and CEO of NeoStem, Inc. (NBS) discusses company strategy and the outlook for this vital industry:

TWST: NeoStem continues to demonstrate its R&D activity. Would you please comment on the technology behind the product candidates Amorcyte, Athelos and VSEL Technology?

Dr. Smith: We're pretty excited about our Amorcyte trial, because we're on track to complete enrollment this year. What we're developing is a cell therapy from bone-marrow-derived stem cells of a person after they have a heart attack. We don't expand the cells, we don't manipulate them, we just isolate out the active ingredient, which is CD34+ CXCR4+ cells, and the mechanism of action is along an SDF-1 gradient, which is highest between day five and 10 after a heart attack.

We take these cells, isolate out the CD34 CXCR4 cells without manipulating or expanding them, stabilize them, send them back to the practitioner within 72 hours so that between days five and 10 they're able to inject these cells into the coronary artery where the person had the infarct. The idea is to prevent that worsening of heart muscle function, because over the age of 45, one in five people with an ST-elevated heart attack will die within a year's time after the heart attack.

TWST: And with regards to the Athelos?

Dr. Smith: Athelos is really exciting. This is not a stem cell therapy; it's actually a Treg therapy. When one's immune system becomes imbalanced, it can cause MS, lupus, steroid-resistant asthma, Type I diabetes. Athelos is a way of taking a person's T-cells and expanding their regulatory cells and giving it back to them in a way that should be able to put a person's immune system back into balance. We were able to fast-track the work that we had to do as a company through our partnership with UCSF and Jeffrey Bluestone, who is working on Type I diabetes in children. There has been some very exciting early results that should allow us to be able to go right into Phase II with him. We are pretty excited about our ability to go quicker into clinical trials, and we'll also be working on steroid-resistant asthma as well, since about half of the people now that have asthma become...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)